Eloxx Pharmaceuticals
Treatment of Rare Genetic Diseases
StartupEloxx Pharmaceuticals is a Ness Ziona-based startup in the Health Tech & Life Sciences sector, established in 2013. Treatment of Rare Genetic Diseases . The company has raised a total of $98.5M across 4 funding rounds, currently at the Public stage. Key investors include Korea Investment Partners, Phil Frost, GF Securities, among 10 total investors. The company has 11-50 employees. Core technologies: Biologicals, Molecules.
With $98.5M in total funding, Eloxx Pharmaceuticals is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Released. The company holds 1 patent.
- StagePublic
- ProductReleased
- ModelB2B
- Employees11-50
- HQNess Ziona
- Last Round$2M
- Korea Investment Partners
- Phil Frost
- GF Securities
10 investors total
55 articles covered by sources including finance.yahoo.com,
www.globenewswire.com,
newsdirect.com,
globenewswire.com,
www.globes.co.il.
What does Eloxx Pharmaceuticals do?
Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases including cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, ataxia-telangiectasia, beta thalassemia, and Tay-Sachs Hurler syndrome. Its platform technologies are uniquely positioned to transform genetic diseases by correcting two defects, nonsense mutations implicated in many rare diseases and ribosomal mutations driving cancer. The companys approach allows it to move rapidly from a target drug-discovery program to clinical drug candidates. Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of genetic diseases caused by nonsense mutations. In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc. This acquisition transitioned Eloxx from a private to a publicly traded company.
How much funding has Eloxx Pharmaceuticals raised?
Eloxx Pharmaceuticals has raised $98.5M in total funding across 4 rounds. The company is currently at the Public stage. Key investors include Korea Investment Partners, Phil Frost, GF Securities.
What sector is Eloxx Pharmaceuticals in?
Eloxx Pharmaceuticals operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals, Molecules. Target customers: Healthcare & Life Sciences, Life Sciences, Biotechnology, Pharmaceuticals, Healthcare, Patients.
Where is Eloxx Pharmaceuticals located?
Eloxx Pharmaceuticals is based in Ness Ziona, Israel. The company also has offices abroad.